Log in
NASDAQ:KRON

Kronos Bio Stock Forecast, Price & News

$28.09
-0.60 (-2.09 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$27.75
Now: $28.09
$28.65
50-Day Range N/A
52-Week Range
$25.50
Now: $28.09
$34.90
Volume86,516 shs
Average Volume426,801 shs
Market Capitalization$1.49 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.60 out of 5 stars

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KRON
CUSIPN/A
CIKN/A
Phone650-781-5200
Employees45

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$1.49 billion
Next Earnings DateN/A
OptionableNot Optionable
$28.09
-0.60 (-2.09 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KRON News and Ratings via Email

Sign-up to receive the latest news and ratings for KRON and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kronos Bio (NASDAQ:KRON) Frequently Asked Questions

Who are some of Kronos Bio's key competitors?

Who are Kronos Bio's key executives?

Kronos Bio's management team includes the following people:
  • Dr. Norbert W. Bischofberger, Pres, CEO & Director (Age 64)
  • Mr. Joshua A. Kazam, Co-Founder & Director (Age 43)
  • Dr. Yasir B. Al-Wakeel, CFO & Head of Corp. Devel. (Age 38)
  • Ms. Barbara A. Kosacz, COO & Gen. Counsel (Age 61)
  • Dr. Christopher Dinsmore, Chief Scientific Officer

When did Kronos Bio IPO?

(KRON) raised $175 million in an IPO on Friday, October 9th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler served as the underwriters for the IPO.

What is Kronos Bio's stock symbol?

Kronos Bio trades on the NASDAQ under the ticker symbol "KRON."

When does the company's quiet period expire?

Kronos Bio's quiet period expires on Wednesday, November 18th. Kronos Bio had issued 13,157,895 shares in its public offering on October 9th. The total size of the offering was $250,000,005 based on an initial share price of $19.00. During the company's quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Kronos Bio?

Shares of KRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kronos Bio's stock price today?

One share of KRON stock can currently be purchased for approximately $28.09.

How big of a company is Kronos Bio?

Kronos Bio has a market capitalization of $1.49 billion. Kronos Bio employs 45 workers across the globe.

What is Kronos Bio's official website?

The official website for Kronos Bio is kronosbio.com.

How can I contact Kronos Bio?

The company can be reached via phone at 650-781-5200.

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.